190 related articles for article (PubMed ID: 15566328)
1. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
File TM; Tillotson GS
Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
[TBL] [Abstract][Full Text] [Related]
2. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
Bhavnani SM; Andes DR
Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
[TBL] [Abstract][Full Text] [Related]
3. Gemifloxacin: a new fluoroquinolone.
Blondeau JM; Missaghi B
Expert Opin Pharmacother; 2004 May; 5(5):1117-52. PubMed ID: 15155113
[TBL] [Abstract][Full Text] [Related]
4. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
Blondeau JM; Tillotson G
Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
[TBL] [Abstract][Full Text] [Related]
5. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
6. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
Zhang L; Wang R; Falagas ME; Chen LA; Liu YN
Chin Med J (Engl); 2012 Feb; 125(4):687-95. PubMed ID: 22490497
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
8. Geminofloxacin for the management of community-acquired respiratory tract infections.
Blondeau JM; Tillotson G; Deangelis J
J Chemother; 2006 Dec; 18(6):582-8. PubMed ID: 17267335
[TBL] [Abstract][Full Text] [Related]
9. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.
Jivcu C; Gotfried M
Int J Chron Obstruct Pulmon Dis; 2009; 4():291-300. PubMed ID: 19684863
[TBL] [Abstract][Full Text] [Related]
10. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
11. Gemifloxacin for community-acquired pneumonia.
Lode HM; Schmidt-Ionas M; Stahlmann R
Expert Opin Investig Drugs; 2008 May; 17(5):779-86. PubMed ID: 18447602
[TBL] [Abstract][Full Text] [Related]
12. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
Wilson R; Schentag JJ; Ball P; Mandell L;
Clin Ther; 2002 Apr; 24(4):639-52. PubMed ID: 12017408
[TBL] [Abstract][Full Text] [Related]
13. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
14. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.
Ball P; Wilson R; Mandell L; Brown J; Henkel T;
J Chemother; 2001 Jun; 13(3):288-98. PubMed ID: 11450888
[TBL] [Abstract][Full Text] [Related]
16. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
17. Gemifloxacin.
Lowe MN; Lamb HM
Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
[TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
File TM; Schlemmer B; Garau J; Cupo M; Young C;
J Antimicrob Chemother; 2001 Jul; 48(1):67-74. PubMed ID: 11474633
[TBL] [Abstract][Full Text] [Related]
20. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
Ball P; Mandell L; Patou G; Dankner W; Tillotson G
Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
